Feb. 7-8, 2024 | Tinkham Veale University Center
You're invited to join us for the Second Annual Case Comprehensive Cancer Center Microbiome Workshop!
This two-day event focuses on the latest developments in microbiome cancer research and covers a diverse range of topics, including:
- Microbiome and Immunity
- Metabolism and the Microbiome
- Therapeutic Implications of Microbiome Modulation
- Translational Approaches in Microbiome Research
Trainees are encouraged to submit abstracts by Dec. 15, 2023, for consideration as posters or short talk presentations. Please limit abstracts to 300 words or less. Abstracts should be submitted through the general registration form.
Stanley Hazen, MD, PhD, received clinical training in Internal Medicine and subspecialty training in Diabetes, Endocrinology and Metabolism from Barnes/Jewish Hospital, St. Louis, MO, and a PhD in Biophysical Chemistry and Molecular Biology from Washington University School of Medicine, St. Louis, MO. He holds multiple leadership positions at the Cleveland Clinic including Chair, Department of Cardiovascular & Metabolic Sciences, Lerner Research Institute; Co-section head, Preventive Cardiology & Rehabilitation, Heart, Vascular & Thoracic Institute; and Director, Center for Microbiome & Human Health. Dr. Hazen sees patients within the Preventive Cardiology Clinic, specializing in preventive cardiovascular medicine care of patients including treatment of hyperlipidemia, hypertension, obesity, and diabetes. His research interests include studies of mechanisms for the development of cardiovascular disease, with an emphasis on understanding the role of the gut microbiome, inflammation, and oxidant stress in the pathogenesis of atherosclerosis and other inflammatory diseases. A renowned physician-scientist, Dr. Hazen has made pioneering discoveries in new understandings of mechanisms contributing to cardiovascular and inflammatory disease research. He is credited with numerous seminal discoveries linking gut microbial pathways to cardiovascular disease pathogenesis, as well as enumerating the role of myeloperoxidase and other inflammatory and oxidative pathways in cardiovascular disease.
Roger Paredes, MD, PhD, is Head of the Infectious Diseases Department, Hospital Germans Trias i Pujol and Principal Investigator of the Microbial Genomics Group at the IrsiCaixa AIDS Research Institute, Badalona, Catalonia, Spain. He obtained an MD, PhD degree in Medicine and Surgery from the Autonomous University of Barcelona (UAB) and specialised in HIV research at the Brigham & Women’s Hospital, Harvard Medical School, through a La Caixa grant for postgraduate studies. His team at irsiCaixa has demonstrated the clinical utility of HIV-1 deep sequencing in both high- and low-income countries and is now leading pioneering research into the role of the gut microbiome in the pathogenesis of HIV infection and chronic inflammation. Dr. Paredes coordinates the 10 million-euro H2020 EU grant MISTRAL (GA- 847943) and is co-PI in 3 grants from the Canadian Institutes of Health Research aimed at disentangling the role of the human microbiome on HIV pathogenesis, transmission, and associated cancers. Since the COVID-19 pandemic, Dr Paredes has been the Spanish National Coordinator of seminal NIH/NIAID-funded randomized clinical trials, including ACTT-1 and 2 and the ACTIV-3/TICO and STRIVE platforms, which have defined the current standard of care for this disease in hospitalized patients as well as in outpatients. His department hosts the largest Long COVID unit in Spain. Dr. Paredes is a member of the WHO HIV Drug Resistance Strategy (ResNet) Steering Committee, the WHO HIV treatment guidelines group, and the WHO Clinical Network on COVID-19. He is a co-author of the Spanish HIV (GESIDA) and COVID-19 (SEIMC) treatment guidelines and is a member of the IAS-USA HIV Drug resistance group. He is Adjunct Associate Professor of the Center for Global Health and Diseases, Department of Pathology, Case Western Reserve University School of Medicine, Cleveland, OH.
Please contact email@example.com with questions.